Hélène Peyro-Saint-Paul
Hoofd Techniek/Wetenschap/O&O bij QIAGEN MARSEILLE
Actieve functies van Hélène Peyro-Saint-Paul
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| QIAGEN MARSEILLE | Hoofd Techniek/Wetenschap/O&O | 26-01-2009 | - |
Loopbaan van Hélène Peyro-Saint-Paul
Eerdere bekende functies van Hélène Peyro-Saint-Paul
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Hoofd Techniek/Wetenschap/O&O | - | - |
Opleiding van Hélène Peyro-Saint-Paul
| Université Fédérale Toulouse Midi-Pyrénées | Doctorate Degree |
| ESSEC Business School | Masters Business Admin |
Statistieken
Internationaal
| Frankrijk | 6 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sectoraal
| Consumer Services | 4 |
| Commercial Services | 2 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
QIAGEN Marseille SA
 QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France. | Commercial Services |
| Université Pierre et Marie Curie | Consumer Services |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Health Technology |
